Join to view full profile
2100 Erwin RdDurham, NC 27705
Phone+1 919-684-8964
Fax+1 919-684-5325
Dr. Lanasa is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
University of Pittsburgh School of MedicineClass of 2002
Certifications & Licensure
MD State Medical License 2017 - 2019
NC State Medical License 2005 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Start of enrollment: 2007 May 10
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Start of enrollment: 2008 Jun 19
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Publications & Presentations
PubMed
- 21 citationsNatural history of monoclonal B-cell lymphocytosis among relatives in CLL families.Susan L. Slager, Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp
Blood. 2021-04-15 - 71 citationsPhase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden
Journal for Immunotherapy of Cancer. 2019-08-23 - 81 citationsActionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, Petra Mayer, S. Pützer
Nature Communications. 2018-02-15
Press Mentions
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025August 27th, 2025- European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal CarcinomaJuly 10th, 2025
- BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025June 2nd, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
